title: Pharmacokinetics of 2',3'-dideoxyadenosine in dogs.
abstract: The pharmacokinetics of 2',3'-dideoxyadenosine (ddAdo) and 2'-3'-dideoxyinosine (ddIno) were determined after intravenous bolus administration and long-term intravenous infusion of ddAdo in dogs. ddAdo was rapidly deaminated to ddIno and ddAdo plasma concentrations were only a fraction of ddIno concentrations. The total body clearance of ddAdo exceeded the literature value for the cardiac output of the dog, indicating an extremely rapid metabolism, and the existence of extrahepatic metabolism. Urinary excretion of unchanged ddAdo was a minor route of elimination (approximately 1%). The pharmacokinetics of ddIno was determined assuming complete conversions of ddAdo to ddIno. ddIno elimination was dose-dependent with total body clearance ranging from 4 to 55 ml/min/kg in individual animals. The plasma half-life was approximately 30 min after most routes of administration, but increased to approximately 60 min in two animals receiving a large intravenous dose of 500 mg/kg. ddIno penetrated into the cerebrospinal fluid to a limited extent, reaching concentrations of 3-11% of those in plasma. Urinary excretion of unchanged ddIno accounted for approximately 20% of the administered dose of ddAdo, while uric acid and hypoxanthine were minor urinary metabolites. Concentrations exceeding the in vitro minimal viral inhibitory concentration (2.4 micrograms/mL) could be safely maintained in plasma for a 10-day period. Infusions which gave cerebrospinal fluid concentrations of 12 to 17 micrograms/mL resulted in dose limiting myelosuppression and intestinal toxicity, after less than 10 days of infusion. Orally administered ddAdo was absorbed as ddIno, with bioavailabilities ranging from 28 to 93% in experiments where no emesis occurred. These studies indicate the rapid in vivo conversion of ddAdo to ddIno, and support the selection of ddIno over ddAdo for further drug development.
authors.affiliation: Department of Surgery, Ohio State University, Columbus 43210.
authors.forename: M G
authors.initials: MG
authors.lastname: Wientjes
authors.forename: M E
authors.initials: ME
authors.lastname: Placke
authors.forename: M J
authors.initials: MJ
authors.lastname: Chang
authors.forename: J G
authors.initials: JG
authors.lastname: Page
authors.forename: W M
authors.initials: WM
authors.lastname: Kluwe
authors.forename: J E
authors.initials: JE
authors.lastname: Tomaszewski
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016049:Didanosine / Q000493:pharmacokinetics* / Q000652:urine; D016048:Dideoxyadenosine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D004285:Dogs; D004355:Drug Stability; D005260:Female; D007262:Infusions, Intravenous; D008297:Male; D013997:Time Factors
chemical_list: D016048:Dideoxyadenosine; D016049:Didanosine